A comparison of overall survival with brexucabtagene autoleucel (Brexu-cel) CAR T-cell therapy (ZUMA-2) and standard of care (SCHOLAR-2) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) previously treated with a covalent bruton tyrosine kinase inhibitor (BTKi)
Authors
Hess, G.Dreyling, M.
Oberic, L.
Gine, E.
Zinzani, P. L.
Linton, Kim M
Vilmar, A.
Jerkeman, M.
Chen, J. M. H.
Ohler, A.
Stilgenbauer, S.
Thieblemont, C.
Lambert, J.
Zilioli, V. R.
Sancho, J. M.
Jimenez-Ubieto, A.
Fischer, L.
Eyre, T. A.
Keeping, S.
Park, J. E.
Wu, J. J.
Siddiqi, R.
Reitan, J.
Castaigne, G.
Salles, G.
Affiliation
Department of Hematology, Oncology and Pneumology, Comprehensive Cancer Center, University Medical School of the Johannes Gutenberg-University, Mainz,Issue Date
2022
Metadata
Show full item recordCitation
Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton KM, et al. A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi). Blood. 2022 Nov;140:10296-9. PubMed PMID: WOS:000893230303139.Journal
BloodDOI
10.1182/blood-2022-162638Additional Links
https://dx.doi.org/10.1182/blood-2022-162638Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2022-162638